Effects of prednisolone on the pharmacokinetics of loratadine after oral and intravenous administration of loratadine in rats

Archives of Pharmacal Research

Volumn 33, Issue 9, 2010, Pages 1395-1400

  Li, Cheng ^a,b   Kim, Minhee ^b   Choi, Jun Shik ^b  

^a YANBIAN UNIVERSITY   (China)

^b Chosun University   (South Korea)

Author keywords

Bioavailability; CYP3A4; Loratadine; P gp; Pharmacokinetics; Prednisolone; Rats

Indexed keywords

CYTOCHROME P450 3A4; GLYCOPROTEIN P; LORATADINE; PREDNISOLONE; RHODAMINE 123;

ANIMAL CELL; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROL GROUP; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG METABOLISM; ENZYME INHIBITION; ENZYME METABOLISM; INTESTINE; LIVER; MALE; NONHUMAN; PROTEIN TRANSPORT; RAT; SINGLE DRUG DOSE;

ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; CELL LINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; HALF-LIFE; HISTAMINE H1 ANTAGONISTS, NON-SEDATING; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INJECTIONS, INTRAVENOUS; LORATADINE; MALE; METABOLIC CLEARANCE RATE; P-GLYCOPROTEIN; PREDNISOLONE; RATS; RATS, SPRAGUE-DAWLEY;

EID: 78449241253     PISSN: 02536269     EISSN: 19763786     Source Type: Journal    
DOI: 10.1007/s12272-010-0913-y     Document Type: Article

References (29)

1. H. Amini A. Ahmadiani 2004 Rapid determination of loratadine in small volume plasma samples by high-performance liquid chromatography with fluorescence detection J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 809 227 230 1:CAS:528:DC%2BD2cXmslamtrY%3D 10.1016/j.jchromb.2004.06.022 15315769
2. C. M. Bradley A. N. Nicholson 1987 Studies on the central effects of the H1-antagonist, loratadine Eur. J. Clin. Pharmacol. 32 419 421 1:CAS:528:DyaL2sXltV2itrc%3D 10.1007/BF00543979 2886343
3. R. A. Carr A. Edmonds H. Shi C. S. Locke L. E. Gustavson J. C. Craft S. I. Harris R. Palmer 1998 Steady-state pharmacokinetics and electrocardiographic pharmacodynamics of clarithromycin and loratadine after individual or concomitant administration Antimicrob. Agents Chemother. 42 1176 1180 1:CAS:528:DyaK1cXislWlurw%3D 9593146
4. S. P. Clissold E. M. Sorkin K. L. Goa 1989 Loratadine, a preliminary review of its pharmacodynamic properties and therapeutic efficacy Drugs 37 42 57 1:CAS:528:DyaL1MXhsVKqu7k%3D 10.2165/00003495-198937010-00003 2523301
5. C. L. Cummins W. Jacobsen L. Z. Benet 2002 Unmasking the dynamic interplay between intestinal P-glycoprotein and CYP3A4 J. Pharmacol. Exp. Ther. 300 1036 1045 1:CAS:528:DC%2BD38XitVelsLs%3D 10.1124/jpet.300.3.1036 11861813
6. B. M. Frey F. J. Frey 1990 Clinical pharmacokinetics of prednisone and prednisolone Clin. Pharmacokinet. 19 126 146 1:STN:280:DyaK3czjs1amtw%3D%3D 10.2165/00003088-199019020-00003 2199128
7. F. J. Frey B. M. Frey 1983 Urinary 6b-hydroxyprednisolone excretion indicates enhanced prednisolone catabolism J. Lab. Clin. Med. 101 593 604 1:CAS:528:DyaL3sXktVSltb8%3D 6833830
8. B. M. Henz 2001 The pharmacologic profile of desloratadine: a review Allergy 56 Suppl65 7 13 10.1034/j.1398-9995.2001.00101.x 11243504
9. J. Hilbert E. Radwanski R. Weglein V. Luc G. Perentesis S. Symchowicz N. Zampaglione 1987 Pharmacokinetics and dose proportionality of loratadine J. Clin. Pharmacol. 27 694 698 1:CAS:528:DyaL1cXjtFagtQ%3D%3D 2960701
10. K. Ito H. Kusuhara Y. Sugiyama 1999 Effects of intestinal CYP3A4 and P-glycoprotein on oral drug absorption; theoretical approach Pharm. Res. 16 225 231 1:CAS:528:DyaK1MXhvFylsbk%3D 10.1023/A:1018872207437 10100307
11. L. S. Kaminsky M. J. Fasco 1991 Small intestinal cytochromes P450 Crit. Rev. Toxocol. 21 407 422 1:STN:280:DyaK387pvVGktA%3D%3D 10.3109/ 10408449209089881
12. A. M. Karssen O. C. Meijer I. C. van der Sandt A. G. De Boer E. C. De Lange E. R. De Kloet 2002 The role of the efflux transporter P-glycoprotein in brain penetration of prednisolone J. Endocrinol. 175 251 260 1:CAS:528:DC%2BD38XosVKjs7s%3D 10.1677/joe.0.1750251 12379510
13. G. G. Kay B. Berman S. H. Mockoviak C. E. Morris D. Reeves V. Starbuck E. Su-kenik A. G. Harris 1997 Initial and steady-state effects of diphenhydramine and loratadine on sedation, cognition, mood, and psychomotor performance Arch. Intern. Med. 157 2350 2356 1:CAS:528:DyaK2sXns1emur0%3D 10.1001/archinte.157.20. 2350 9361576
14. T. Kosoglou M. Salfi J. M. Lim V. K. Batra M. N. Cayen M. B. Affrime 2000 Evaluation of the pharmacokinetics and electrocardiographic pharmacodynamics of loratadine with concomitant administration of ketoconazole or cimetidine Br. J. Clin. Pharmacol. 50 581 589 1:CAS:528:DC%2BD3MXkvVyqug%3D%3D 10.1046/j.1365-2125.2000.00290.x 11136297
15. W. Kreutner J. A. Hey J. Anthes A. Barnett S. Young S. Tozzi 2000 Preclinical pharmacology of desloratadine, a selective and nonsedating histamine H1 receptor antagonist. 1st communication: Receptor selectivity, antihistaminic activity, and antiallergenic effects Arzneimittelforschung 50 345 352 1:CAS:528:DC%2BD3cXjtFSlsro%3D 10800633
16. S. Madsbad B. Bjerregaard J. H. Henriksen E. Juhl H. Kehlet 1980 Impaired conversion of prednisone to prednisolone in patients with liver cirrhosis Gut 21 52 56 1:STN:280:DyaL3c7lslygug%3D%3D 10.1136/gut.21.1.52 7364321
17. A. Nakayama O. Eguchi M. Hatakeyama H. Saitoh M. Takada 1999 Different absorption behaviors among steroid hormones due to possible interaction with P-glycoprotein in the rat small intestine Biol. Pharm. Bull. 22 535 538 1:CAS:528:DyaK1MXjsFShu74%3D 10375178
18. E. E. Philpot 2000 Safety of second generation antihistamines Allergy Asthma Proc. 21 15 19 1:CAS:528:DC%2BD3cXitFWhtrc%3D 10.2500/108854100778249033 10748947
19. L. Pichard G. Gillet I. Fabre I. Dalet-Beluche C. Bonfils J. P. Thenot P. Maurel 1990 Identification of the rabbit and human cytochromes P-450IIIA as the major enzymes involved in the N-demethylation of diltiazem Drug Metab. Dispos. 18 711 719 1:CAS:528:DyaK3MXlsFagug%3D%3D 1981725
20. L. Pichard I. Fabre M. Daujat J. Domergue H. Joyeux P. Maurel 1992 Effect of corticosteroids on the expression of cytochromes P450 and on cyclosporin A oxidase activity in primary cultures of human hepatocytes Mol. Pharmacol. 41 1047 1055 1:CAS:528:DyaK38Xls1Citrk%3D 1614409
21. B. M. Prenner D. Capano A. G. Harris 2000 Efficacy and tolerability of loratadine versus fexofenadine in the treatment of seasonal allergic rhinitis: A-double-blind comparison with crossover treatment of nonresponders Clin. Ther. 22 760 769 1:CAS:528:DC%2BD3cXlvVyitb0%3D 10.1016/S0149-2918(00)90009-2 10929922
22. J. G. Ramaekers M. M. Uiterwijk J. F. O'Hanlon 1992 Effects of loratadine and cetirizine on actual driving and psychometric test performance, and EEG during driving Eur. J. Clin. Pharmacol. 42 363 369 1:CAS:528:DyaK38Xks1aks70%3D 1355427
23. V. J. Wacher J. A. Silverman Y. Zhang L. Z. Benet 1998 Role of P-glycoprotein and cytochrome P450 3A in limiting oral absorption of peptides and peptidomimetics J. Pharm. Sci. 87 1322 1330 1:CAS:528:DyaK1cXltlyhsb0%3D 10.1021/js980082d 9811484
24. E. J. Wang C. N. Casciano R. P. Clement W. W. Johnson 2001 Evaluation of the interaction of loratadine and desloratadine with P-glycoprotein Drug Metab. Dispos. 29 1080 1083 1:CAS:528:DC%2BD3MXlsVChtLw%3D 11454724
25. D. J. Waxman C. Attisano F. P. Guengerich D. P. Lapenson 1988 Human liver microsomal steroid metabolism: identification of the major microsomal steroid hormone 6bhydroxylase cyto-chrome P-450 enzyme Arch. Biochem. Biophys. 263 424 436 1:CAS:528:DyaL1cXkvVKnt7o%3D 10.1016/0003-9861(88)90655-8 3259858
26. B. Wolozin W. Kellman P. Ruosseau G. G. Celesia G. Siegel 2000 Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors Arch. Neurol. 10 1439 1443 10.1001/archneur.57. 10.1439
27. C. R. Yates C. Chang J. D. Kearbey K. Yasuda E. G. Schuetz D. D. Miller J. T. Dalton P. W. Swaan 2003 Structural determinants of P-glycoprotein-mediated transport of glucocorticoids Pharm Res. 20 1794 1803 1:CAS:528: DC%2BD3sXptVChtLk%3D 10.1023/B:PHAM.0000003377.39548.f6 14661924
28. O. Q. Yin X. Shi M. S. Chow 2003 Reliable and specific high-performance liquid chromatographic method for simultaneous determination of loratadine and its metabolite in human plasma J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 796 165 172 1:CAS:528:DC%2BD3sXnvVyls7Y%3D 10.1016/j.jchromb.2003.08.023 14552827
29. N. Yumibe K. Huie K. J. Chen M. Snow R. P. Clement M. N. Cayen 1996 Identification of human liver cytochrome P450 enzymes that metabolize the nonsedating antihistamine loratadine. Formation of descarboethoxyloratadine by CYP3A4 and CYP2D6 Biochem. Pharmacol. 51 165 172 1:CAS:528:DyaK28XltFOnug%3D%3D 10.1016/0006-2952(95)02169-8 8615885